Drug Delivery

Drug release refers to the process by which an active substance administered in a dosage form (e.g. tablet, capsule, implant) exits the form and exerts its effect under controlled or uncontrolled conditions. This process involves three fundamental steps: disintegration of the dosage form, disaggregation of particles, and dissolution.

^{Controlled drug release (generated by Artificial Intelligence)}

Controlled release systems aim to deliver the active substance at a predetermined rate and maintain constant plasma concentrations. They improve patient compliance by 40-85% and reduce the frequency of daily dosing by 50-75%.

• Diffusion-controlled systems: Systems in which the drug is slowly released via diffusion through a water-permeable membrane or matrix. They operate according to Fick’s laws and are mathematically described by the equation Q = KD·A·ΔC·t/h (KD: diffusion coefficient, A: surface area, ΔC: concentration gradient, h: membrane thickness).
• Matrix systems: Systems in which the drug is homogeneously dispersed within a polymeric matrix. Production costs are 15-30% lower than conventional dosage forms and they are widely used in industrial manufacturing. They are classified into hydrophobic and hydrophilic matrix systems.
• Reservoir-diffusion systems: Systems in which the drug is contained in a central reservoir surrounded by a polymeric coating with controlled permeability. These systems provide zero-order kinetics and maintain a constant release rate for 12-24 hours.
• Swelling-controlled systems: Systems in which drug release is regulated by volume expansion of a hydrophilic polymer matrix upon contact with water. Swelling ratios range from 200-800%, and the thickness of the gel layer determines the release rate.
• Osmotic-controlled systems: Systems that deliver the drug at a constant rate using a semi-permeable membrane and osmotic pressure. They follow the equation dM/dt = k₀ (zero-order kinetics) and operate independently of pH or changes in gastrointestinal motility. Clinical studies show 95% bioavailability.
• Chemical or enzymatic-controlled systems: Release occurs through degradation of the polymer chain by hydrolysis or specific enzymatic action. Used for colon-specific drug delivery and suitable for targeted therapy approaches. Degradation time ranges from 2-12 hours.

Higuchi Equation (diffusion-based approach): The equation Q = KH · √t, used in diffusion-controlled matrix systems, calculates the cumulative amount of drug released over time. KH is the Higuchi constant, dependent on the drug’s diffusion coefficient, solubility, and matrix porosity. This model is valid for 20-80% release and shows a correlation coefficient R² > 0.95. Limitations of the Higuchi model include assumptions of a homogeneous matrix, the requirement of sink conditions, and complete dissolution. Due to these limitations, the Korsmeyer-Peppas model is preferred for complex release profiles.

Zero-Order Kinetics: Constant release rate independent of time, observed in osmotic and reservoir systems: dM/dt = k₀. This kinetic type is critical for drugs with a narrow therapeutic window (e.g. warfarin, digoxin).

• Chitosan derivatives: A natural polymer with biodegradable, biocompatible, and mucoadhesive properties. Enzymatic degradation time is 2-8 hours with minimal toxicity risk (LD₅₀ > 16 g/kg). It is insoluble at gastric pH but soluble at intestinal pH.
• Hydroxypropyl methylcellulose (HPMC): Exhibits chemical stability across pH 3-11. Gel viscosity ranges from 4000 to 100000 cP. It has a safe toxicity profile (GRAS status) and is classified in pregnancy category A.
• Polymers such as ethyl cellulose, polyvinyl acetate, and HPC: Commonly used in diffusion and swelling-type systems.

Controlled release systems account for 37% of the total prescription drug market. Metformin XR formulations used in diabetes mellitus treatment have increased patient compliance by 73% and reduced gastrointestinal side effects by 45%.

Controlled release is essential for drugs with short half-lives (t½ < 4 hours). For example, while the half-life of propranolol is 3-6 hours, a controlled release formulation provides an effect duration of 12 hours.

Nanotechnology-based approaches include liposomes, nanocrystals, and polymeric nanoparticles. These systems are advancing targeted drug delivery and personalized medicine applications. Production costs are 200-400% higher than conventional systems.

Modern manufacturing technologies include 3D printing, electrospinning, and microencapsulation. These technologies enable the development of patient-specific dosage forms.

Drug release encompasses the entire process from disintegration of the dosage form to dissolution in the surrounding medium. Controlled release systems offer significant advantages in maintaining effective plasma levels, improving patient compliance, and reducing side effects. The release mechanism and type of polymer used directly influence the drug’s delivery profile.